eMedicine Specialties > Pediatrics: General Medicine > Endocrinology
Growth Hormone Deficiency: Differential Diagnoses & Workup
Updated: Sep 15, 2008
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
Differential Diagnoses
Other Problems to Be Considered
Familial (genetic) short stature
Constitutional delay of growth
Short stature accompanying systemic disease
Short stature as part of a genetic syndrome
Short stature related to endocrinopathy (eg, hypothyroidism, Cushing syndrome)
Short stature related to a metabolic abnormality (ie, renal tubular acidosis, poorly controlled diabetes mellitus)
Short stature from abuse and neglect
Workup
Laboratory Studies
- Thyroxine and thyroid-stimulating hormone: Hypothyroidism should be excluded as a cause of growth failure and short stature.
- Serum electrolytes: A low bicarbonate level may indicate renal tubular acidosis, which can result in growth failure. Abnormal electrolytes may indicate renal failure.
- CBC count and sedimentation rate: These studies may be helpful if inflammatory bowel disease is suspected.
- IGF-1 and IGFBP-3
- Both IGF-1 and IGFBP-3 are growth hormonedependent.
- Low values of IGF-1 and IGFBP-3 suggest growth hormone deficiency (GHD). However, a low value alone is not diagnostic because IGFs are sensitive to other factors such as nutritional state and chronic systemic disease.
- Karyotype
- Girls with otherwise unexplained short stature should have a karyotype study to rule out Turner syndrome.
- Although many girls with Turner syndrome are diagnosed from signs upon physical examination, the only recognizable feature of many girls with the condition is short stature.
- In particular, girls with mosaic karyotypes or karyotypes with isochromosomes tend to exhibit fewer signs specific to Turner syndrome.
- Many girls with Turner syndrome, and particularly those with mosaic karyotypes and karyotypes other than 45,X, do not demonstrate the striking stigmata associated with Turner syndrome.
Imaging Studies
- MRI of the head
- Patients diagnosed with growth hormone deficiency should undergo an MRI of the head to exclude a brain tumor (eg, craniopharyngioma).
- Approximately 15% of patients with growth hormone deficiency have an abnormality of the pituitary gland (eg, ectopic bright spot, empty or small sella).
Other Tests
- Bone age determination
- Comparison of a left hand and wrist radiograph to standards can be used to estimate skeletal maturation.
- With familial short stature, bone age is comparable to chronological age. Bone age is usually delayed in children with constitutional growth delay, malnutrition, and endocrine causes of short stature (eg, hypothyroidism, cortisol excess, growth hormone deficiency).
- Bone age also allows determination of growth potential as adult stature may be estimated from the Bayley-Pinneau tables.
- Growth hormone provocative testing
- Growth hormone response to insulin is the most reliable test for growth hormone deficiency.
- Before accepting growth hormone deficiency diagnosis, many insurance companies require a documented failure to demonstrate a growth hormone response (with a growth hormone level >10 ng/mL) after presentation of 2 provocative stimuli.
- Provocative stimuli include insulin-induced hypoglycemia, arginine, levodopa (L-dopa), clonidine, and glucagon.
More on Growth Hormone Deficiency |
| Overview: Growth Hormone Deficiency |
Differential Diagnoses & Workup: Growth Hormone Deficiency |
| Treatment & Medication: Growth Hormone Deficiency |
| Follow-up: Growth Hormone Deficiency |
| References |
| « Previous Page | Next Page » |
References
Mills JL, Schonberger LB, Wysowski DK. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr. Apr 2004;144(4):430-6. [Medline].
Rainbow LA, Rees SA, Shaikh MG. Mutation analysis of POUF-1, PROP-1 and HESX-1 show low frequency of mutations in children with sporadic forms of combined pituitary hormone deficiency and septo-optic dysplasia. Clin Endocrinol (Oxf). Feb 2005;62(2):163-8. [Medline].
Blethen SL, Allen DB, Graves D. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab. May 1996;81(5):1704-10. [Medline].
Frindik JP, Baptista J. Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics. Oct 1999;104(4 Pt 2):1000-4. [Medline].
Root AW, Kemp SF, Rundle AC. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study. J Pediatr Endocrinol Metab. 1998;11:403-12.
Lindsay R, Feldkamp M, Harris D. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. Jul 1994;125(1):29-35. [Medline].
Cuttler L, Silvers JB, Singh J, Marrero U, Finkelstein B, Tannin G, et al. Short stature and growth hormone therapy. A national study of physician recommendation patterns. JAMA. Aug 21 1996;276(7):531-7. [Medline].
Grimberg A, Stewart E, Wajnrajch MP. Gender of pediatric recombinant human growth hormone recipients in the United States and globally. J Clin Endocrinol Metab. Jun 2008;93(6):2050-6. [Medline].
Tanner JM, Whitehouse RH, Hughes PC. Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner''s syndrome, and other complaints. Arch Dis Child. Dec 1971;46(250):745-82. [Medline].
Blethen SL, Compton P, Lippe BM. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab. Mar 1993;76(3):574-9. [Medline].
Cheng JC, Leung SS, Lau J. Anthropometric measurements and body proportions among Chinese children. Clin Orthop. Feb 1996;(323):22-30. [Medline].
Frasier SD. A preview of growth hormone stimulation tests in children. Pediatrics. Jun 1974;53(6):929-37. [Medline].
Frasier SD, Costin G, Lippe BM. A dose-response curve for human growth hormone. J Clin Endocrinol Metab. Dec 1981;53(6):1213-7. [Medline].
Frindik JP, Kemp SF, Pihoker C. Effective use of magnetic resonance imaging in the assessment of children with possible growth hormone deficiency. Endocrine Practice. 1996;2:8-12.
Hintz RL. The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metab. Aug 1995;80(8):2298-301. [Medline].
Kemp SF. Growth hormone therapeutic practice: dosing issues. The Endocrinologist. 1996;6:231-7.
Rabin MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endrocrinol Metab. 1958;18:901-3.
Reiter EO, Martha PM Jr. Pharmacological testing of growth hormone secretion. Horm Res. 1990;33(2-4):121-6; discussion 126-7. [Medline].
Rosenbloom AL, Knuth C, Shulman D. Growth hormone therapy by daily injection in patients previously treated for growth hormone deficiency. South Med J. 1980;83:653-5.
Rosenfeld RG, Albertsson-Wikland K, Cassorla F. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab. May 1995;80(5):1532-40. [Medline].
Rosenfeld RG, Wilson DM, Lee PD. Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr. Sep 1986;109(3):428-33. [Medline].
Siklar Z, Tuna C, Dallar Y, Tanyer G. Zinc deficiency: a contributing factor of short stature in growth hormone deficient children. J Trop Pediatr. Jun 2003;49(3):187-8. [Medline].
Further Reading
Keywords
growth hormone deficiency GH deficiency, GHD, hypopituitarism, hypopituitary dwarfism, Creutzfeldt-Jakob disease, septooptic dysplasia, SOD, de Morsier syndrome, encephalitis, meningitis, craniopharyngioma, leukemia, CNS malformation, CNS tumor, histiocytosis, CNS infection, short stature, hypoglycemia, intrauterine growth retardation, malnutrition, delayed puberty, Turner syndrome, Noonan syndrome, Russell-Silver syndrome
Differential Diagnoses & Workup: Growth Hormone Deficiency